IL-18 BP antagonizes IL-18, leading to a decrease in fIL-18 in the bone marrow microenvironment of patients with MDS, affecting CD8+ T-cell function, which is closely related to MDS severity; therefore, it may become a new target for MDS treatment. Here, IL18 is linked to myelodysplastic syndrome.